An implantable medical device in Australia must meet safety and performance requirements to gain market approval. From 25 November 2021, active implantable medical devices have been reclassified from Class AIMD to Class III. These high-risk devices require substantial clinical and technical evidence to demonstrate their safety, quality, and intended function.
Sponsors and manufacturers must prepare documentation showing that the device meets the TGA’s Essential Principles. These principles cover areas such as medical device design integrity, biocompatibility, and long-term performance once implanted.
Meeting Essential Principles for These Devices
Compliance with the Essential Principles involves detailed clinical data, validated design controls, and evidence of long-term stability for Class III medical devices. The device must be sterile, reliable over its intended duration, and safe for use within the human body.
Supporting materials must be clearly documented and traceable across the product’s lifecycle. Missing or inconsistent data can delay or prevent ARTG inclusion, which is mandatory before supply in Australia.
Plan Proactively to Avoid Compliance Gaps
If you’re introducing an implantable medical device in Australia, early alignment with Essential Principles gives you a better chance at regulatory success. For Class III medical devices, these requirements are especially rigorous. Build your submission around strong evidence and structured planning to support timely approval.